Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors; D010880:Piperidines / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology*
D010726:Phosphodiesterase Inhibitors; D010880:Piperidines; D011799:Quinazolines; D015105:3',5'-Cyclic-AMP Phosphodiesterases